ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Monday, November 18, 2024

10:30AM-12:30PM: Abstract Number: 2226

Site-specific Differences in the Association of Non-vertebral Major Osteoporotic Fractures and Rheumatoid Arthritis

RA – Diagnosis, Manifestations, & Outcomes Poster III

10:30AM-12:30PM: Abstract Number: 1824

Skin Macrophage Subtypes and Impact of Tofacitinib in Early Diffuse Cutaneous Systemic Sclerosis: Results from Single-cell Analyses of an Observational Data Set and a Phase I/II Randomized Controlled Trial

Systemic Sclerosis & Related Disorders – Basic Science Poster II

10:30AM-12:30PM: Abstract Number: 2517

Skin Microbiome Shows Differences Between Pathergy Positive and Negative Patients with Behçet’s Syndrome

Vasculitis – Non-ANCA-Associated & Related Disorders Poster III

10:30AM-12:30PM: Abstract Number: 1793

SLE Patient Serum and SLE-associated Danger Signals Impair Efferocytosis in Human Macrophages

SLE – Etiology & Pathogenesis Poster

10:30AM-12:30PM: Abstract Number: 1923

Social Determinants of Health Documentation and Prevalence Among Rheumatology Patients Seen in a Southern Medical Center

Healthcare Disparities in Rheumatology Poster III

10:30AM-12:30PM: Abstract Number: 2086

Specific Transcriptomic Profile Associated with Disease Activity in Muscle Biopsies from Patients with Sarcoid Myopathy

Muscle Biology, Myositis & Myopathies – Basic & Clinical Science Poster III

10:30AM-12:30PM: Abstract Number: 1828

SSc Fibroblasts Trigger a Systemic Type I Interferon Response in SSc Patients Through Canonical TGF-β Receptor Signalling

Systemic Sclerosis & Related Disorders – Basic Science Poster II

10:30AM-12:30PM: Abstract Number: 1766

STAT2-Associated Type I Interferonopathy: A Masquerade of Infectious Susceptibility

Pediatric Rheumatology – Basic Science Poster

10:30AM-12:30PM: Abstract Number: 1880

Statewide Burden of Osteoarthritis in India and Its Trend from 1990-2021: A Benchmarking Analysis

Epidemiology & Public Health Poster III

10:30AM-12:30PM: Abstract Number: 2260

Statin Use in Patients with Rheumatoid Arthritis (RA) and Osteoarthritis: Are RA Patients More Likely to Receive Statins?

RA – Treatment Poster III

10:30AM-12:30PM: Abstract Number: 2125

Strengthening Fracture Risk Prediction in Rheumatoid Arthritis: Integrating a Self-report Sarcopenia Screening Tool (SARC-F) and Fracture Risk Assessment Tool (FRAX) Scores

Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science Poster

10:30AM-12:30PM: Abstract Number: 2251

Stress-Related Neural Activity Measured with FDG-PET/CT Is Associated with Articular Disease Activity, Systemic Inflammation, and Treatment-associated Change in Arterial Inflammation in Rheumatoid Arthritis

RA – Diagnosis, Manifestations, & Outcomes Poster III

10:30AM-12:30PM: Abstract Number: 2145

Study of Bone Metabolism in Patients Diagnosed with Osteogenesis Imperfecta.

Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science Poster

10:30AM-12:30PM: Abstract Number: 2465

Subclinical Loss of Lung Volumes in Very Early SSc: Evidence from Two Independent Cohorts in EUSTAR

Systemic Sclerosis & Related Disorders – Clinical Poster III

10:30AM-12:30PM: Abstract Number: 2277

Switching to a Targeted Drug with a Different Mode of Action After Discontinuation of the First TNF Inhibitor Is Associated with Better Drug Survival Compared to a Second TNF Inhibitor in Rheumatoid Arthritis: A Propensity Score-matched Analysis from the Czech ATTRA Registry

RA – Treatment Poster III

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].